Ignite Creation Date:
2024-05-06 @ 9:12 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02927340
Status:
UNKNOWN
Last Update Posted:
2021-03-09
First Post:
2016-09-26
Brief Title:
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Organization Data
Organization:
Massachusetts General Hospital
Class:
OTHER
Study ID:
16-248
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Massachusetts General Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Ibiayi Dagogo-Jack MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Massachusetts General Hospital
Old Name:
None
Old Organization:
None